ABBV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AbbVie Inc (ABBV) is not a strong buy at this moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has positive catalysts such as FDA approvals and a strong dividend, the technical indicators suggest a bearish trend, and recent congressional trading shows cautious sentiment. It is better to wait for a more favorable entry point or clearer bullish signals.
The MACD is negatively expanding at -0.73, RSI is at 33.082 indicating neutral to bearish momentum, and moving averages are converging. The stock is trading close to its S1 support level of 217.343, with resistance at 223.112. The short-term trend suggests further downside potential.
FDA approval for Skinvive, a hyaluronic acid injectable for neck wrinkles, which expands the company's product portfolio.
Quarterly dividend of $1.73 per share, reflecting a commitment to shareholder returns.
Positive analyst ratings with multiple firms maintaining Buy or Overweight ratings and price targets ranging from $234 to $298.
The stock has shown a bearish price trend recently, with a regular market change of -2.14%.
Congress trading data shows more sale transactions than purchases, indicating cautious sentiment.
Technical indicators suggest a potential further decline in the short term.
No financial data available for the latest quarter.
Analysts remain generally positive on AbbVie, with multiple firms maintaining Buy or Overweight ratings. Price targets range from $234 to $298, reflecting confidence in the company's growth prospects, particularly in immunology and IBD pipelines.
